



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

623.MANTLE CELL, FOLLICULAR, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL**Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?**

Francesco Autore¹, Alessandra Tedeschi², Giulia Benevolo, MD³, Veronica Mattiello, MD⁴, Eugenio Galli⁵, Nicolò Danesin, MD⁶, Rita Rizzi⁷, Jacopo Olivieri⁸, Emanuele Cencini⁹, Benedetta Puccini, MD¹⁰, Isacco Ferrarini, MD PhD¹¹, Dario Marino, MD PhD¹², Martina Bullo¹³, Bernardo Rossini¹⁴, Marina Motta, MD¹⁵, Idanna Innocenti, PhD¹⁶, Luca Stirparo, MD¹⁷, Diego Petrilli¹⁷, Raffaella Pasquale¹⁸, Pellegrino Musto, MD⁷, Greta Scapinello, MD¹⁹, Alessandro Noto, MD²⁰, Veronica Peri, MD²¹, Giulia Zamprognà²², Stefan Hohaus²³, Annamaria Frustaci, MD²⁴, Francesco Piazza, MD²⁵, Simone Ferrero, MD²⁶, Luca Laurenti, MD²⁷

¹ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

² ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

³ University Hematology Division, Citta' della Salute e della Scienza Hospital, Torino, Italy, Torino, Italy

⁴ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

⁵ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

⁶ Azienda Ospedale Università di Padova, Padova, Italy

⁷ Università di Bari "Aldo Moro," A.O.U. Consorziato Policlinico di Bari, Bari, Italy

⁸ Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

⁹ A.O.U. Senese and University of Siena, Siena, ITA

¹⁰ A.O.U. Careggi, Firenze, Italy

¹¹ A.O.U. Integrata di Verona - Borgo Roma,, Verona, Italy

¹² Oncologia 1, IRCCS Istituto Oncologico Veneto, Padova, Italy

¹³ A.O. Ordine Mauriziano di Torino, Turin, ITA

¹⁴ IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy

¹⁵ Hematology, ASST Spedali Civili, Brescia, Italy

¹⁶ Fondazione Universitaria Policlinico A Gemelli di Roma, Roma, Roma, Italy

¹⁷ Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

¹⁸ Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

¹⁹ Department of Medicine, Hematology Unit, University of Padova, Padova, Italy, Padova, ITA

²⁰ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

²¹ Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy

²² ASST Grande Ospedale Metropolitano Niguarda Hospital, Milano, ITA

²³ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

²⁴ Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

²⁵ University of Padua, Padova, Italy

²⁶ Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

²⁷ Division of Hematology, Fondazione Universitaria Policlinico A Gemelli di Roma, Rome, Italy

Waldenström Macroglobulinaemia (WM) is an indolent lymphoma still primarily managed with chemo-immunotherapy, which remains a key first-line treatment option, although recently BTKIs have emerged as potential therapies for untreated patients. The aim of our study was to evaluate and compare efficacy and safety of different chemo-immunotherapeutic regimens commonly used in Italy for frontline WM treatment.

A retrospective analysis was conducted on 547 WM patients enrolled between 2008-2022 from 14 Italian haematological centres. Among them, 245 received the BR scheme (bendamustine-rituximab), 116 were treated with DRC (dexamethasone-rituximab-cyclophosphamide), and 129 were treated with various other regimens including monotherapy with chlorambucil or cyclophosphamide as well as more aggressive combinations, such as Chl-R (chlorambucil-rituximab), FCR (fludarabine-cyclophosphamide-rituximab) or R-CHOP (rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone), 48 patients received rituximab monotherapy for neurological symptoms.

The main focus of our analysis was on the two major treatment groups: BR and DRC.

There were notable differences between these two groups in terms of age at treatment (69 vs 70 years old, respectively), CIRS (more patients with CIRS>6 in DRC) and revised IPSSWD (higher risk rates in BR). Patients treated with BR tended to be younger, more fit but also had a more aggressive disease.

Overall survival (OS) curves did not show significant differences between the two schemes (5-year OS 87.5% for BR and 93.0% for DRC, $p=0.42$). Similarly, the analysis of progression free survival (PFS) curves demonstrated a better PFS at 5 years for BR (79.2%) compared to DRC (54.5%) ($p<0.001$; figure 1A). The median PFS was 63.6 months for DRC, while it was not reached for BR. When analysing BR-treated patients separately (standard dose and reduced initial dose) both groups showed better PFS curves than DRC ($p<0.001$; figure 1B).

Multivariate analysis identified the choice of the treatment (BR vs DRC) as the sole significant variable impacting PFS (RR 1.76). Notably, approximately 33% of the patients treated with BR received an initial bendamustine dose lower than the standard dose of 90 mg/m² for first-line therapy with 91% of these cases receiving 70 mg/m². The two schemes BR and DRC were well tolerated with no significant reduction in administered cycles (16.3% for BR vs 20.7% for DRC). However, dose reduction was more common for BR (14.3%) compared to DRC (6.0%).

In conclusion, this large Italian retrospective real-life study showed excellent outcomes for unselected WM patients treated with chemo-immunotherapy. Despite the emergence of new treatment options, chemo-immunotherapy remains a highly effective treatment modality for these patients. The long-term follow-up confirmed better PFS for BR-treated patients, while OS, remained comparable between BR and DRC. Moreover, the BR scheme exhibited excellent PFS even with a reduced initial bendamustine dose.

Disclosures Tedeschi: Astrazeneca: Speakers Bureau; **Abbvie:** Speakers Bureau; **Beigene:** Speakers Bureau; **Janssen:** Speakers Bureau. **Ferrero:** Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **EUSA Pharma:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Abbvie:** Consultancy; **Sandoz:** Consultancy; **Beigene:** Research Funding; **Morphosys:** Research Funding; **Incyte:** Membership on an entity's Board of Directors or advisory committees; **Clinigen:** Membership on an entity's Board of Directors or advisory committees; **Servier:** Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Gentili:** Speakers Bureau; **Italfarmaco:** Membership on an entity's Board of Directors or advisory committees.

<https://doi.org/10.1182/blood-2023-179460>




Figure 1